HELSINKI, March 12, 2026 (GLOBE NEWSWIRE) — Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects, announced today the first patient has been dosed in its Phase 2a ‘HEALING’ clinical trial in peripheral arterial occlusive disease (PAOD) leading to chronic limb threatening ischemia (CLTI).

The single- and repeat- dose study using an intravenous (IV) administration taking place in Finland, is for up to 42 patients across 4 cohorts and has been designed to provide a preliminary indication of safety and efficacy of APAC in CLTI patients (with and without revascularisation) as well as APAC’s effect on thrombo-inflammatory biomarkers. Atherosclerosis-related thrombo-inflammation lead to CLTI, a severe form of PAOD, with insufficient blood flow in the affected limb, which can indicate limb amputation and has a mortality rate of 25% in the first year. The most important risk factors are diabetes and cigarette smoking.

This new Phase 2a trial received FIMEA approval following the successful completion of an international Phase 1 clinical trial in 30 healthy participants, which demonstrated that APAC was well tolerated, with dose-dependent and transient systemic antithrombotic effects. An associated PET-imaging clinical trial with ⁸⁹zirconium-labeled APAC in PAOD patients and healthy participants is due to complete in H1 2026.

Aki Prihti, CEO at Aplagon, said, “We’re delighted to have achieved this significant clinical milestone and dosed our first patient in our Phase 2a trial to treat PAOD/CLTI. These are common, serious, thrombo-inflammatory diseases with high morbidity. Our innovative approach, using a heparin proteoglycan mimetic with targeting ability and retention on the vascular injury sites, has potential applications across a broad range of serious vascular diseases caused by thrombo-inflammation. Importantly, our APAC technology can be easily administered locally or intravenously in the hospital setting, supporting its uptake by vascular surgeons or angiologists.”

Maarit Venermo, Professor of vascular surgery, MD, PhD at Helsinki University Hospital, University of Helsinki, commented on the study, “The aim of this study is to improve the current treatment of PAOD/CLTI. APAC has been shown to prevent platelet aggregation and blood clotting. Previous studies have also shown that it reduces the inflammatory response in tissues damaged by oxygen deprivation during short follow-ups. Through these actions, APAC enhances the medical treatment of lower limb arterial atherosclerosis, accelerate the healing of tissue damage caused by ischemia, and prevent restenosis after revascularization procedures, thereby reducing the need for reinterventions.”

PAOD is relatively common and, as it progresses, can lead to limb threatening ischemia, significantly increasing the risk of amputation if arterial perfusion is not improved by a revascularization procedure. Arterial occlusions are often caused by atherosclerotic plaque formation, which may be aggravated by platelet aggregation at sites of severe stenosis, worsening limb ischemia. Current treatments for PAOD do not cure the disease but only alleviate symptoms. Revascularization procedures are often effective; however, particularly after endovascular treatment, restenosis occurs in approximately one-third of treated arteries, even when patients are on antithrombotic medication according to current treatment guidelines. The occurrence of restenosis and microvascular dysfunction represent a significant Achilles’ heel of endovascular treatment, leading to not only suffering for patients but also considerable societal costs.

Aplagon is also planning for 2026 a Phase 2 clinical trial for arteriovenous fistula (AVF) maturation failure in Europe, following the successful completion of its Phase 1 AVF trial. The study demonstrated encouraging early maturation results with no safety concerns.

About Aplagon Oy

Aplagon is a clinical stage biotech company developing a first-in-class therapeutic, called APAC (anti-platelet and anticoagulant), for treating thrombo-inflammatory diseases. The company’s two lead indications are for the prevention of arteriovenous fistula (AVF) maturation failure, to enable lifesaving haemodialysis treatment in end-stage kidney disease patients, and for chronic limb threatening ischemia (CLTI). By mimicking naturally occurring mast cell-derived heparin proteoglycans, APAC targets arterial injury sites providing long-lasting antithrombotic and anti-inflammatory action in situ. APAC is intended for in-hospital use and can be administered either locally or by IV infusion.

APAC is based on the pioneering research on mast cell-derived heparin proteoglycans performed by Prof. Riitta Lassila and associates at Wihuri Research Institute in Helsinki, Finland. Aplagon is backed by a syndicate of leading Nordic investors including FSG Fund, Wihuri Foundation, Innovestor and Serlachius Foundation as well as EIC Fund. The company is headquartered in Helsinki, Finland.

For more information see our website and LinkedIn.

Media Contacts

Aplagon

Aki Prihti, CEO
aki.prihti@aplagon.com

Scius Communications
Katja Stout +44 7789435990
katja@sciuscommunications.com

Daniel Gooch +44 7747875479
daniel@sciuscommunications.com

The post Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia appeared first on Crypto Insider.

Homary UK – Premier Physical Storefront in Chiswick, London

LONDON, March 12, 2026 (GLOBE NEWSWIRE) — Homary, a global provider of home furniture and décor products, today announced the grand opening of its first UK flagship store. The 3,000 sq ft showroom, located at 323-327 Chiswick High Road in west London, opens to the public on March 14, 2026, marking the brand’s official entry into the UK retail market.

Guided by its philosophy, “Your Life: Beautifully Practical,” the store features furniture and décor organized around relatable ‘life personas‘—including ‘The Life and Soul’ and ‘The Social Battery Saver’—supported by illustrations and interactive displays such as a photo wall, magnetic elements, and mirrored stations. This curated approach, inspired by the MBTI personality framework, allows visitors to explore collections tailored to different lifestyles

Homary MBTI Furniture – Personalized Furniture for Every Persona

The product range includes living room, dining, bedroom, bathroom, and outdoor furniture designed to suit a variety of UK living spaces, from city apartments to rural homes.

Homary Outdoor Furniture – Versatile Collections Reflecting Spring Outdoor Living Trends

“Britain approaches interiors with a focus on practicality and understated elegance,” said Susi Wang, CEO of Homary. “Our Chiswick flagship reflects that sensibility and provides personality-driven options for customers across the country.”

Store Details

• Address: 323-327 Chiswick High Road, London W4 4HH
• Opening Hours: Monday–Saturday: 9:00 AM–6:00 PM; Sunday: 11:00 AM–5:00 PM
• Opening Period Highlights: Complimentary welcome gifts for visitors (while supplies last); discounts of up to 18% on qualifying purchases; prize draw entries for vouchers up to £600 on spends over £3,000

The flagship follows an initial soft launch earlier in 2026 and complements Homary’s established online presence in the UK, with the official opening period including complimentary gifts, discounts on qualifying purchases, and a prize draw for vouchers up to £600.

About Homary

Homary is a global home lifestyle brand specializing in furniture and home décor products that empower personal expression in living spaces. Operating in over 15 markets worldwide, the company combines international design aesthetics with accessible pricing. For more information on the UK collection and the flagship store, visit https://uk.homary.com

Media Contact:
Homary
Homary Marketing Team
pr@homary.com
https://uk.homary.com/

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/570ee6d8-7f39-4550-b969-2839ccd1d4bf

https://www.globenewswire.com/NewsRoom/AttachmentNg/8c3fd87f-b4a2-4300-9ca9-310f37d39621

https://www.globenewswire.com/NewsRoom/AttachmentNg/86ae90a9-795f-4e68-8b48-1e35e6598b61

The post Homary Announces Opening of First UK Flagship Store in Chiswick, London, on March 14, 2026 appeared first on Crypto Insider.

Facephi’s Vision for 2026: A Structural Winner in a Rapidly Evolving, AI-Enabled Digital Identity and Fraud-Prevention Market

• 2025, a Catalyst Year: Facephi evolved from a biometric company into a comprehensive digital identity and fraud-prevention platform, creating a unique 360° approach to risk management.
• AI-Driven Advantage: Amid debate over AI’s disruption to many business models, Facephi benefits from rising demand for certified and secure solutions. Its continuously learning platform transforms AI-driven risk into a structural competitive advantage.
• Mission-Critical Infrastructure: Deployed at the core of regulated industries, where failure results in financial, regulatory, and reputational damage; identity solutions cannot be commoditized or delegated to generic, non-certified, or non-auditable AI platforms.

Alicante, March 11, 2026 – Facephi (BME Growth: FACE; Euronext Growth Paris: ALPHI), a global leader in digital identity verification and fraud prevention, publishes its Investor Positioning 2026, highlighting its structural advantage in an AI-driven market.

This release comes amid growing investor debate over AI’s impact on traditional technology business models. While AI is disrupting many sectors, Facephi’s 360° certified platform, regulatory expertise, and continuous risk management architecture are structurally reinforced by these changes.

Facephi operates at the intersection of digital identity, fraud prevention, and compliance in regulated industries; where any mistake carries direct financial, legal, and reputational consequences. In these contexts, identity solutions must be auditable, resilient, and embedded within regulated workflows; they cannot be commoditized or delegated to generic AI platforms.

Javier Mira, CEO of Facephi, commented: “2025 was transformative, as Facephi evolved into a comprehensive digital identity and fraud-prevention platform. AI strengthens our relevance in an environment of increasingly sophisticated fraud.

This positioning enables us to grow well above the industry average, with sustained 25%+ growth, margin expansion through scale, and positive cash flow from 2026; and we are just getting started.”

Facephi’s architecture leverages continuous learning and adaptive risk management, turning AI from a threat into a structural competitive advantage. By combining biometrics, AI, and ML-driven decision engines in an end-to-end platform, Facephi is building the mission-critical identity infrastructure required for an AI-driven, regulated digital economy at scale and at the right moment in the market cycle. Organizations that fail to adapt risk being left behind.

To access the full document, please click of the following link: FACEPHI – Investor Positioning 2026

About Facephi

Facephi is a technology company specializing in digital identity verification, fraud prevention, and regulatory compliance solutions. It delivers an AI/ML-powered Identity & Anti-Fraud platform that provides a comprehensive 360° end-to-end approach to digital protection. Renowned for its strong focus on security and data integrity, Facephi develops solutions that make digital processes safer, more accessible, and fraud-free. Its technologies help prevent identity theft while ensuring the ethical management and protection of personal data.

With over a decade of experience in developing technologies aimed at safeguarding digital identity, Facephi is headquartered in Spain, with subsidiaries in APAC, EMEA, and LATAM. The company serves the needs of clients across 30+ countries, delivering innovative solutions that address security challenges in an ever-evolving digital landscape.

Forward-Looking Statements

This press release may contain forward-looking statements regarding Facephi’s future plans, objectives, and financial performance. Actual results may differ materially due to various risks and uncertainties. Please refer to the company’s filings for a discussion of these risks.

The post Facephi’s Vision for 2026: A Structural Winner in a Rapidly Evolving, AI-Enabled Digital Identity and Fraud-Prevention Market appeared first on Crypto Insider.

• The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries.
• Expanded collaboration provides future co-development opportunities.

COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs). This agreement builds on the existing mpox vaccine license and manufacturing agreement with SII, and replaces the agreement previously entered with Biological E. Limited.

In addition, through this expanded collaboration, the parties will explore potential future co-development opportunities.

“We are pleased to strengthen our strategic partnership with Serum Institute of India. By leveraging the strengths of both organizations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe,” said Paul Chaplin, President & CEO of Bavarian Nordic.

About CHIKV VLP
CHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination.

The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination.

CHIKV VLP (marketed as Vimkunya^®) has been approved by the U.S. Food and Drug Administration, the European Commission and the U.K. Medicines & Healthcare products Regulatory Agency in 2025. Regulatory review of the vaccine is ongoing in Switzerland and Canada.

About chikungunya
Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries¹. Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years². In 2025, as of December, nearly 500,000 cases of chikungunya and over 200 associated deaths were reported worldwide³. More than half of the reported cases and associated deaths were reported from Brazil⁴. Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile⁵.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.

About Serum Institute of India
Serum Institute of India Pvt. Ltd. is the world’s largest vaccine manufacturer, developing life-saving vaccines against diseases including polio, measles, meningitis, rotavirus, diphtheria, tetanus, malaria, HPV, pneumonia, and COVID-19, with a mission to make affordable vaccines accessible worldwide. Present across 170+ countries, including the U.S., the UK, and Europe, SII operates one of the largest multifunctional vaccine production facilities in Manjri, Pune, with an annual capacity of 4 billion doses, contributing to saving over 30 million lives over the years. For more information, visit www.seruminstitute.com.

Contact investors:
Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

¹ World Health Organization (WHO). Chikungunya.https://www.who.int/news-room/fact-sheets/detail/chikungunya   

² European Centre for Disease Prevention and Control. Chikungunya virus disease. https://www.ecdc.europa.eu/en/chikungunya-virus-disease.

³ European Centre for Disease Prevention and Control. Chikungunya virus disease worldwide overview. https://www.ecdc.europa.eu/en/chikungunya-monthly.

⁴ Pan American Health Organization (PAHO). Chikungunya: analysis by country.  https://www.paho.org/en/arbo-portal/chikungunya-data-and-analysis/chikungunya-analysis-country

⁵ Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701.

Attachment

• Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

The post Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement appeared first on Crypto Insider.

Dubai , UAE, March 10, 2026 (GLOBE NEWSWIRE) — Techysquad has expanded its SEO and digital visibility services to help small and mid-sized enterprises (SMEs) tackle the growing challenge of rising customer acquisition costs (CAC) across major digital advertising platforms. As businesses worldwide continue to reassess their marketing strategies amid increasing competition and higher advertising expenses, the company has been offering structured SEO solutions designed to support long-term organic growth and sustainable online visibility. These services focus on helping businesses reduce reliance on paid advertising while building a stronger and more consistent presence in organic search results.

As digital advertising costs continue to rise globally, small and mid-sized enterprises (SMEs) are increasingly reassessing how they allocate their marketing budgets. Industry analysts note that customer acquisition costs (CAC) across major digital platforms have steadily increased over the past few years, prompting businesses to explore more sustainable, long-term marketing strategies.

According to digital solutions firm Techysquad, this shift is leading more companies to prioritize search engine optimization (SEO) and organic visibility as foundational growth channels rather than relying solely on paid advertising.

The Shift from Short-Term Traffic to Long-Term Visibility

Paid advertising remains an effective growth lever for many businesses. However, rising competition and auction-based pricing models have made performance marketing more expensive and less predictable, particularly for startups and SMEs operating with limited budgets.

“Businesses are recognizing that while paid campaigns can deliver immediate traffic, sustainable growth often depends on building long-term search authority,” said a spokesperson from Techysquad. “SEO is no longer viewed as optional—it has become a core strategic asset for companies aiming to reduce long-term acquisition costs.”

SEO strategies typically involve technical website optimization, content development, keyword targeting, and improving overall site performance to align with search engine ranking factors.

Algorithm Evolution and the Importance of Quality Content

Search engine algorithms have evolved significantly, placing greater emphasis on user experience, content relevance, technical performance, and authority signals. As a result, companies are being required to adopt more structured and data-driven approaches to digital marketing.

Techysquad notes that businesses investing in technical SEO audits, structured content strategies, and user experience optimization are seeing stronger long-term positioning in competitive search landscapes.

“Search visibility is increasingly tied to credibility,” the company representative added. “Brands that consistently produce relevant, high-quality content and maintain strong technical foundations are better positioned to compete in digital markets.”

Digital Marketing as Infrastructure, Not Campaign

Another emerging trend is the shift in mindset from campaign-based marketing to infrastructure-based marketing. Rather than focusing solely on short-term promotional pushes, businesses are building digital ecosystems that include:

• Optimized websites
• Structured content hubs
• Mobile-responsive platforms
• Analytics-driven decision-making frameworks

Techysquad works with startups and SMEs to implement integrated digital marketing strategies that combine SEO, website optimization, and performance analysis to support scalable growth.

Looking Ahead

As digital competition intensifies, experts suggest that companies prioritizing sustainable visibility and long-term brand authority may be better positioned to manage fluctuating advertising costs.

Industry observers expect SEO and structured digital marketing frameworks to remain central components of business growth strategies in 2026 and beyond.

Linkedin |  X | Youtube | Instagram | Facebook

Media Contact:
https://techysquad.com/
Contact@techysquad.com

The post Techysquad Announces New SEO Strategy Services to Help Businesses Manage Rising Customer Acquisition Costs appeared first on Crypto Insider.

Hyderabad, March 10, 2026 (GLOBE NEWSWIRE) — The global molecular diagnostics market is witnessing significant expansion as healthcare systems increasingly adopt advanced diagnostic technologies to detect diseases at the genetic and molecular level. According to Mordor Intelligence, the molecular diagnostics market size is estimated to reach USD 20.41 billion in 2026 and is projected to expand to USD 33.51 billion by 2031, registering a CAGR of 10.43% during the forecast period, driven by increasing prevalence of infectious and chronic diseases, and rapid advancements in genomic and molecular testing technologies. 

Molecular diagnostics plays a critical role in modern healthcare by enabling accurate detection of pathogens, genetic mutations, and biomarkers associated with various diseases. These tests support early diagnosis and personalized treatment planning, particularly in areas such as oncology, infectious diseases, genetic disorders, and prenatal testing. The growing focus on precision medicine and targeted therapies is further strengthening the adoption of molecular diagnostic tools across hospitals, laboratories, and research institutions worldwide. Technological innovation remains a key factor supporting market growth. Advancements in automated diagnostic platforms, rapid molecular testing kits, and portable diagnostic devices are improving laboratory efficiency and expanding testing capabilities. The integration of digital health platforms and advanced data analytics is also enhancing diagnostic accuracy and enabling more efficient disease monitoring. 

Molecular Diagnostics Market Share by Region 

North America holds a significant share of the molecular diagnostics market due to advanced healthcare infrastructure, strong research funding, and high adoption of innovative diagnostic technologies. 

Europe represents another key market, supported by expanding research initiatives, growing emphasis on early disease detection, and the increasing use of molecular testing in clinical diagnostics. 

Asia-Pacific is expected to witness notable growth during the forecast period, driven by expanding healthcare infrastructure, rising investments in biotechnology, and increasing awareness of advanced diagnostic technologies. 

Other regions including the Middle East, Africa, and South America are also gradually adopting molecular diagnostic technologies as healthcare systems strengthen disease surveillance and diagnostic capabilities. 

Molecular Diagnostics Market Trends & Forecast 

Growing Demand for Early Disease Detection 

Healthcare providers are increasingly utilizing molecular diagnostic tools to detect diseases at earlier stages, improving treatment outcomes and supporting preventive healthcare strategies. 

Advancements in Genomic and Molecular Testing Technologies 

Innovations in PCR technologies, sequencing platforms, and automated diagnostic systems are improving testing speed, accuracy, and scalability. 

“Molecular diagnostics adoption is expanding as healthcare providers prioritize earlier detection and more informed treatment decisions. Mordor Intelligence uses transparent research frameworks and multi-source validation, giving executives a dependable basis for comparing market outlooks.” Says, Soumya Goud, Senior Research Manager, Mordor Intelligence 

Molecular Diagnostics Market Segmentation Overview 

By Technology 

• Next-Generation Sequencing (NGS) 

• In Situ Hybridization 

• Chips & Microarrays 

• Mass Spectrometry 

• Other Technologies 

By Application 

• Infectious Disease 

• Oncology 

• Pharmacogenomics 

• Microbiology 

• Genetic Disease Screening 

• Human Leukocyte Antigen Typing 

• Blood Screening 

By Product 

• Reagents & Kits 

• Instruments & Systems 

• Software & Services 

By Sample Type 

• Blood, Serum & Plasma 

• Other Sample Types (Saliva, Tissue, Swabs) 

By End User 

• Hospitals 

• Diagnostic & Reference Laboratories 

• Academic & Research Institutes 

• Other End Users 

By Geography 

• North America 

• United States 

• United Kingdom 

• Rest of Europe 

• Asia-Pacific 

• South Korea 

• Australia 

• Rest of Asia-Pacific 

• Middle East and Africa 

• South Africa 

• Rest of Middle East and Africa 

• South America 

• Argentina 

• Rest of South America 

For a full breakdown of market dynamics, segmentation insights, regional analysis, and competitive landscape, access the details of the Mordor Intelligence report: https://www.mordorintelligence.com/industry-reports/molecular-diagnostics-market?utm_source=globenewswire 

Molecular Diagnostics Market Competitive Outlook 

The molecular diagnostics market features a combination of global diagnostic companies and biotechnology firms focusing on product innovation, research collaborations, and expansion of advanced diagnostic platforms. Companies are investing in automated testing systems, rapid molecular diagnostic kits, and next-generation sequencing technologies to strengthen their market presence and support the growing demand for precision diagnostics. 

Molecular Diagnostics Companies include: 

• Abbott Laboratories   

• F. Hoffmann-La Roche Ltd   

• Thermo Fisher Scientific Inc.   

• Danaher Corporation   

• Qiagen N.V.   

• Bio-Rad Laboratories   

• Hologic Inc.   

• Siemens Healthineers   

• Agilent Technologies Inc.   

• Illumina Inc. 

Check out related reports published by Mordor Intelligence 

Next-Generation Cancer Diagnostics Market Size  – The next-generation cancer diagnostics market stood at USD 15.34 billion in 2024 and is projected to reach USD 34.87 billion by 2030, growing at a CAGR of 9.6%. Market growth is driven by increasing cancer prevalence, rising adoption of genomic and molecular testing technologies, and expanding use of precision medicine approaches in oncology diagnostics. 
 

Cervical Dysplasia Market Share  – The cervical dysplasia market is estimated at USD 0.82 billion in 2026 and is projected to reach USD 1.14 billion by 2031, registering a CAGR of 6.78% during the forecast period. Growth is supported by increasing screening programs, rising awareness of cervical cancer prevention, and expanding adoption of diagnostic and treatment procedures for precancerous cervical conditions. 
 

Point-of-Care Molecular Diagnostics Market Trends  – The point-of-care molecular diagnostics market is estimated to grow from USD 4.65 billion in 2026 to USD 7.97 billion by 2031, registering a CAGR of 11.37% during the forecast period. Market expansion is driven by increasing demand for rapid diagnostic testing, growing prevalence of infectious diseases, and rising adoption of decentralized testing solutions in clinical settings. 

F. Hoffmann-La Roche Ltd, Danaher Corporation, Thermo Fisher Scientific Inc., BioMérieux SA and Abbott Laboratories are the major companies operating in this market. 

Read more about companies in the point-of-care molecular diagnostics market: https://www.mordorintelligence.com/industry-reports/point-of-care-molecular-diagnostics-market/companies?utm_source=globenewswire 

About Mordor Intelligence:    

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategicgoals.    
    
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.    

The post Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence appeared first on Crypto Insider.

Euronext announces volumes for February 2026

Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 9 March 2026 – Euronext, the leading European capital market infrastructure, today announced trading volumes for February 2026.

Monthly and historical volume tables are available at this address:

euronext.com/investor-relations#monthly-volumes

CONTACTS  

ANALYSTS & INVESTORS – ir@euronext.com

Investor Relations        Judith Stein        +33 6 15 23 91 97

        Margaux Kurver        +33 6 84 16 85 03        

MEDIA – mediateam@euronext.com 

Europe        Andrea Monzani         +39 02 72 42 62 13 

        Sandra Machado        +351 917 776 897

Belgium        Marianne Aalders         +32 26 20 15 01                 

France, Corporate        Flavio Bornancin-Tomasella        +33 1 70 48 24 45                 

Greece        Ioulia Zafolia         +30 694 570 1070

Ireland        Catalina Augspach        +33 6 82 09 99 70                        

Italy         Ester Russom         +39 02 72 42 67 56                 

The Netherlands        Marianne Aalders         +31 20 721 41 33                 

Norway         Cathrine Lorvik Segerlund        +47 41 69 59 10                 

Portugal         Sandra Machado        +351 917 776 897         

About Euronext  

Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway and Portugal. In November 2025, Euronext acquired a majority stake in the Athens Stock Exchange (ATHEX), reinforcing its pan-European footprint and further extending its fully integrated market infrastructure with the addition of an exchange, a CSD and a clearing house.

As of February 2026, Euronext’s regulated exchanges in Belgium, France, Greece, Ireland, Italy, the Netherlands, Norway and Portugal host over 1,800 listed issuers with €7 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 29% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices.

For the latest news and resources, please visit the Media Centre. Follow us on X and LinkedIn for regular updates.

Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided “as is”, without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.

© 2026, Euronext N.V. – All rights reserved. 

The Euronext Group processes your personal data in order to provide you with information about Euronext (the “Purpose”). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, “GDPR”), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.

Attachment

• Euronext PR Volumes – February 2026

The post Euronext announces volumes for February 2026 appeared first on Crypto Insider.

Founded on March 9, 1966, in Marseille by Pierre Bellon, Sodexo is celebrating today 60 years of a visionary model that has, over the decades, led it to become one of the global leaders in food and services. The Group now supports companies, healthcare and educational institutions, public organizations, as well as iconic venues and events, delivering services that improve consumers’ daily lives at every moment: work, heal, learn, and play.

Today present in 43 countries and employing nearly 430,000 people, Sodexo continues to grow around a constant ambition: being a trusted long-term partner for its clients, addressing their strategic priorities – attracting and retaining talents, supporting development and operational performance, while integrating ever – more sustainable solutions.

“For 60 years, Pierre Bellon’s legacy has guided our actions: to be useful to our clients and consumers by addressing their real needs and critical challenges. In a world undergoing profound transformation, this commitment drives us to design ever more effective, responsible, and value-creating solutions. This is how Sodexo continues to support its clients with pragmatism, commitment, and a strong sense of service.” — Thierry Delaporte, Chief Executive Officer of Sodexo

Sodexo continues to grow, driven by the long-standing commitment of the Bellon family, the reference shareholder through Bellon SA, ensuring its independence and a long-term vision.

On this occasion, Sodexo is publishing a press kit retracing its history and illustrating how the Group now supports its clients as they face new challenges: “Sodexo: 60 years shaping better everyday experiences”.

About Sodexo

Founded in Marseille in 1966 by Pierre Bellon, Sodexo is the leader in Food and Services, shaping better everyday experiences at every moment in life: work, heal, learn and play. The Group stands out for its independence, its founding family shareholding and its responsible business model. With its services, Sodexo meets all the challenges of everyday life with a dual goal: to improve the quality of life of our employees and those we serve, and contribute to the economic, social and environmental progress in the communities where we operate. For Sodexo, growth and social commitment go hand in hand. Our purpose is to create a better everyday for everyone to build a better life for all. Sodexo is included in the CAC Next 20, CAC SBT 1.5, FTSE 4 Good and DJSI indices.

Sodexo key figures

Contacts

Attachment

• PR – Sodexo celebrates its 60th anniversary – ENG

The post Sodexo celebrates its 60th anniversary appeared first on Crypto Insider.

BENGALURU, KA, March 08, 2026 (GLOBE NEWSWIRE) — BENGALURU, KA – March 08, 2026 – –

Access to safe drinking water remains a daily priority for households across Delhi NCR, but the way residents acquire water purification systems is beginning to change. Instead of purchasing water purifiers outright, a growing number of households are exploring alternatives such as water purifier rental in Delhi. The shift reflects rising awareness around the long-term costs of ownership and a preference for flexible subscription-based services that simplify maintenance and servicing.

One of the companies driving this shift is Rentomojo, one of India’s leading furniture and appliance rental platforms, which now offers water purifiers on rent across Delhi NCR through flexible monthly subscription plans designed for urban households.

Traditionally, purchasing a water purifier in Delhi requires an upfront investment of approximately ₹15,000 to ₹20,000 depending on the model and filtration technology. However, the purchase price represents only the initial cost. Households typically need to account for additional expenses such as annual maintenance contracts, filter replacements, membrane changes, and periodic servicing. These ongoing costs can range from ₹4,000 to ₹6,000 per year depending on usage and water quality conditions.

Over a five-year period, the effective cost of owning a purifier can exceed ₹35,000 to ₹40,000 once maintenance and replacement components are included. In regions such as Delhi NCR, where high total dissolved solids (TDS) levels often require frequent filter replacement, these costs can rise even further.

For renters and families who relocate frequently within the NCR region, ownership introduces additional complications. Dismantling, transporting, and reinstalling water purifiers can require professional servicing, and warranty coverage does not always transfer seamlessly when equipment is moved between locations. These factors have led many urban residents to reconsider whether purchasing a purifier outright is the most practical option.

In response, Rentomojo has expanded its water purifier rental services in Delhi, offering households access to purification systems through predictable monthly subscription plans. Rather than purchasing equipment, customers can rent a water purifier and pay a fixed monthly fee that includes installation, maintenance support, and servicing.

Rentomojo’s water purifier rental portfolio includes multiple purification technologies designed to address varying water conditions in Delhi. These include RO, UV, UF, and alkaline purification systems that combine multiple filtration stages to improve drinking water quality.

The company offers several models, including advanced multi-stage purifiers such as DriftLux seven-stage filtration systems, alkaline mineral-enhanced RO purifiers, and dual RO and UF purification units designed to treat high-TDS water commonly found in the region. Rentomojo also offers purifiers from established brands including Kent and Livpure alongside its own models.

Monthly rental pricing typically ranges from approximately ₹458 to ₹708 depending on the model selected and the purification technology required. The subscription structure is designed to eliminate several common pain points associated with appliance ownership. Rentomojo provides home delivery, professional installation, and maintenance coverage, allowing customers to avoid separate servicing arrangements and unexpected repair costs.

Every purifier delivered through the platform undergoes quality checks before installation, and units are provided in new or excellent condition. Maintenance support, filter servicing, and repair assistance are included within the subscription model, helping ensure consistent purification performance without additional charges.

For customers who relocate within Delhi NCR, the company also offers relocation support, allowing subscribers to transfer their purifier to a new residence without needing to purchase new equipment. Flexible rental tenures are available, including monthly, quarterly, and longer-term plans, allowing customers to choose a duration that suits their living arrangements.

The model is particularly attractive to young professionals, students, interns, freelancers, and families living in rented apartments, where long-term ownership of appliances may not align with changing housing situations.

Renting a purifier through Rentomojo follows a simplified process. Customers can browse available models through the Rentomojo website or mobile app, choose a suitable purifier, select a rental tenure, complete the KYC verification process, and schedule delivery and installation at a convenient time.

In a city where water quality varies significantly across neighborhoods due to infrastructure differences and high TDS levels, reliable purification technology remains essential for everyday health and safety. At the same time, urban consumption patterns are evolving as consumers prioritize flexibility, predictable monthly costs, and service-based access to household essentials.

Industry observers note that the transition toward subscription-based appliance access reflects broader shifts seen in other sectors, where access-based models are replacing traditional ownership. For many Delhi NCR households, water purifier rental is increasingly viewed as a practical alternative that provides access to reliable purification technology without the financial commitment and logistical challenges associated with ownership.

As awareness of lifetime appliance costs continues to grow, services such as Rentomojo’s water purifier rental offering are emerging as a flexible solution for households seeking continuous access to clean drinking water without the upfront investment traditionally required to purchase purification systems. To learn more visit: https://www.rentomojo.com/

###

For more information about Rentomojo Private Limited, contact the company here:

Rentomojo Private Limited
Dhruv Wahal
+91 1800 102 6601
jo@rentomojo.com
Rentomojo Private Limited
B Wing- 4th Floor, BHIVE Workspace,
WJ88+69V BMTC Complex,
Old Madiwala, Kuvempu Nagar, Stage 2, BTM Layout,
Bengaluru, Karnataka – 560068

The post Rentomojo Expands Water Purifier Rental Services in Delhi NCR, Offering RO, UV, and Alkaline Systems From ₹401/Month appeared first on Crypto Insider.

NEW YORK, March 08, 2026 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Mereo class action, go to https://rosenlegal.com/submit-form/?case_id=52452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants’ statements included, among other things, confidence in setrusumab’s ability to ultimately reduce the annualized fracture rates of the tested patients and in the study itself to put setrusumab in an opportunity to succeed in reaching statistical significance of this key endpoint.

The defendants, the lawsuit claims, provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit their primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively. Such statements absent these material facts caused investors to purchase Mereo’s ADSs at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Mereo class action, go to https://rosenlegal.com/submit-form/?case_id=52452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

The post ROSEN, A LEADING AND RANKED FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO appeared first on Crypto Insider.